Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19…
First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19…